

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 1/21/11 has been entered.

Information Disclosure Statement

The information disclosure statement (IDS) submitted on 1/21/11 and 5/24/11 are in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statements have been considered by the examiner.

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

The application has been amended as follows:

- 1) In the specification, page 1, before the 1st line, following is inserted:
- - This application is a 371 of PCT/JP04/12416, filed 08/23/2004. - -

The following is an examiner's statement of reasons for allowance: The closest prior art is RN 160647-76-7, which teaches pyridine containing compound which is


structurally similar to claimed in herein. However, applicants have proviso out the compound. See below:

L40 ANSWER 17 OF 79 HCAPLUS COPYRIGHT 2010 ACS on SIN
ACCESSION NUMBER: 1997:533640 HCAPLUS Full-text
DOCUMENT NUMBER: 127:220659
ORIGINAL REFERENCE NO.: 127:43005a, 43008a
TITLE: Quinoline and benzimidazole derivatives as bradykinin agonists
INVENTOR(S): Oki, Teruo; Kayakiri, Hiroshi; Abe, Yoshito; Sawada, Yuki; Mizutani, Tsuyoshi
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 98 pp.
CODEN: PINKDG
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
NO 9728153	A1	19970807	WO 1997-JP233	19970131 <--
W: AU, CA, CN, JP, KR, MX, US				
RU: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9715569	A	19970822	AU 1997-15569	19970131 <--
EP 879233	A1	19981125	EP 1997-901799	19970131 <--
EP 879233	B1	20030613		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2001513749	T	20010904	JP 1997-527493	19970131 <--
JP 4092732	B2	20080528		
AT 247105	T	20030615	AT 1997-901799	19970131 <--
ES 2202573	T3	20040401	ES 1997-901799	19970131 <--
US 6015618	A	20000118	US 1998-217453	19980803 <--
US 6127339	A	20001003	US 1999-422075	19991021 <--
PRIORITY APPL. INFO.:			GE 1996-2029	A 19960201 <--
			WO 1997-JP233	W 19970131 <--
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S):		MARKAT 127:220659		

1002-0012

- AB The invention relates to compds. I [Q = ring fusions Q1 or Q2; R1 = H, alkyl, halo; R2 = alkyl, halo; R3 = amino substituted with alkyl, acyl, or -2AR11; R4 = heterocycloalkyl; R5 = alkyl; R6 = acylalkyl, aralkyl, heterocycloalkyl; R7 = alkyl, alkoxy; R11 = amino, acylamino; R1 = alkylene; A2 = alkylene, bond; Z = alkenylene, 1,2-pyrrolediy1, C6H4, or 2,3-thiophenediy1, latter 3 with optional halo substitution] and their pharmaceutically acceptable salts. Also disclosed are processes for preparation of the compds., pharmaceutical compns. comprising them, and methods of therapeutic use in the prevention and/or treatment of hypertension and the like. For instance, etherification of 2-(hydroxymethyl)pyridine with 4-chloro-5-hydroxy-2-methylquinoline gave 8-hydroxy-2-methyl-4-(2-pyridylmethoxy)quinoline, which was further etherified with 2,6-dichloro-3-[N-[[[4-(methoxycarbonyl)cinnamoyl]glycyl]-N-methylamino]benzyl bromide to give title compound II. In an assay for inhibition of [3H]-bradykinin binding to guinea pig ileum receptors in vitro, II had an IC50 of 9.9 ± 10-10 M.
- IT 160647-76-7
RL: RCT (Reactant); S&T (Reactant or reagent)
(starting material; preparation of quinoline and benzimidazole derivs. as bradykinin agonists)
RN 160647-76-7 HCAPLUS
CN Carbamic acid, [3-[(4-pyridinylamino)carbonyl]phenyl]-, phenyl ester (SCI)
(CA INDEX NAME)



Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to SHAILENDRA KUMAR whose telephone number is (571)272-0640. The examiner can normally be reached on Mon-Fri/5-4-9.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sullivan Daniel can be reached on (571)272-0779. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

S. Kumar
12/5/11

/SHAILENDRA KUMAR/
Primary Examiner, Art Unit 1621